StockNews.com Initiates Coverage on Cutera (NASDAQ:CUTR)

Research analysts at StockNews.com started coverage on shares of Cutera (NASDAQ:CUTR) in a note issued to investors on Friday. The firm set a “sell” rating on the medical device company’s stock.

Cutera Stock Up 3.9 %

Shares of Cutera stock opened at $0.36 on Friday. Cutera has a 12 month low of $0.28 and a 12 month high of $4.97. The business has a fifty day simple moving average of $0.47 and a 200 day simple moving average of $0.90. The stock has a market cap of $7.34 million, a PE ratio of -0.06 and a beta of 1.26.

Institutional Trading of Cutera

A number of hedge funds have recently modified their holdings of the company. Ground Swell Capital LLC bought a new stake in Cutera in the second quarter valued at approximately $37,000. Squarepoint Ops LLC grew its holdings in shares of Cutera by 164.5% in the 2nd quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock valued at $172,000 after buying an additional 70,870 shares during the period. Finally, Bank of Montreal Can grew its holdings in shares of Cutera by 14.2% in the 2nd quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock valued at $455,000 after buying an additional 35,248 shares during the period. 90.70% of the stock is currently owned by institutional investors and hedge funds.

Cutera Company Profile

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.